Fresh analysis reveals that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who end conventional lifestyle regimens.
Research printed in a major health publication demonstrates that while overweight people frequently drop a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"Individuals buying such drugs should be cognizant of the risk of fast weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a return to original mass within about a year and a half.
Comparing Treatments
The research, which looked at 37 of studies involving over 9,000 of participants, contrasted the results of these new drugs with other pills.
The team note that people who shed pounds through dieting usually have a less rapid weight regain—approximately 100 grams monthly—after stopping.
Explaining the Quick Regain
Experts believe the way of the injections is key to understanding the accelerated weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal might result in the body to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in hunger is unsuppressed, making binge eating far more likely."
A Lifelong Disease?
The NHS advise the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts say that, considering the significant potential of relapse, the treatment might need to be life-long.
This opinion is echoed by pharmaceutical companies, who say that the results "highlight the long-term character of excess weight," akin to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the jabs explain a powerful resurgence of appetite.
"It was like a switch flipping and I was suddenly extremely hungry," described an individual.
The struggle is worsened if individuals have not established sustainable lifestyle or habit changes during therapy.
Widespread Adoption
Survey data indicate that millions of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is higher among women than males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers caution that while the jabs are effective agents for weight loss, they are not a magic fix and long-term success relies on combined lifestyle management.
